| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/31/2023 | -20.39% | Goldman Sachs | $11 → $18 | Maintains | Neutral |
| 06/21/2023 | 1.72% | HC Wainwright & Co. | → $23 | Reiterates | Buy → Buy |
| 05/15/2023 | -2.7% | Oppenheimer | → $22 | Reiterates | Outperform → Outperform |
| 05/15/2023 | 1.72% | HC Wainwright & Co. | → $23 | Reiterates | Buy → Buy |
| 05/02/2023 | 1.72% | HC Wainwright & Co. | → $23 | Reiterates | → Buy |
| 04/10/2023 | 1.72% | HC Wainwright & Co. | → $23 | Reiterates | → Buy |
| 02/16/2023 | 1.72% | HC Wainwright & Co. | → $23 | Reiterates | → Buy |
| 02/08/2023 | -55.77% | Jefferies | $35 → $10 | Downgrades | Buy → Hold |
| 12/12/2022 | 1.72% | HC Wainwright & Co. | $26 → $23 | Maintains | Buy |
| 04/27/2022 | -11.54% | Berenberg | → $20 | Initiates Coverage On | → Buy |
| 03/22/2022 | -51.35% | Goldman Sachs | $10 → $11 | Maintains | Neutral |
| 01/18/2022 | 50.38% | HC Wainwright & Co. | $50 → $34 | Maintains | Buy |
| 04/27/2021 | 121.14% | HC Wainwright & Co. | $57 → $50 | Maintains | Buy |
| 04/17/2020 | 107.87% | Oppenheimer | $45 → $47 | Maintains | Outperform |
| 04/16/2020 | 152.1% | HC Wainwright & Co. | $53 → $57 | Reiterates | → Buy |
| 04/13/2020 | 134.41% | HC Wainwright & Co. | $75 → $53 | Maintains | Buy |
| 04/06/2020 | 99.03% | Oppenheimer | $47 → $45 | Maintains | Outperform |
| 01/13/2020 | 129.99% | Oppenheimer | $62 → $52 | Maintains | Outperform |
| 11/13/2019 | 72.49% | JP Morgan | $40 → $39 | Maintains | Neutral |
| 05/30/2019 | 81.34% | JP Morgan | → $41 | Initiates Coverage On | → Neutral |
| 05/29/2019 | 121.14% | Goldman Sachs | → $50 | Initiates Coverage On | → Neutral |
| 01/29/2019 | 262.67% | HC Wainwright & Co. | → $82 | Initiates Coverage On | → Buy |
| 11/08/2018 | 240.56% | Jefferies | → $77 | Assumes | → Buy |
| 09/14/2018 | 209.6% | Stifel | → $70 | Initiates Coverage On | → Buy |
What is the target price for UroGen Pharma (URGN)?
The latest price target for UroGen Pharma (NASDAQ: URGN) was reported by Goldman Sachs on July 31, 2023. The analyst firm set a price target for $18.00 expecting URGN to fall to within 12 months (a possible -20.39% downside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for UroGen Pharma (URGN)?
The latest analyst rating for UroGen Pharma (NASDAQ: URGN) was provided by Goldman Sachs, and UroGen Pharma maintained their neutral rating.
When is the next analyst rating going to be posted or updated for UroGen Pharma (URGN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of UroGen Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for UroGen Pharma was filed on July 31, 2023 so you should expect the next rating to be made available sometime around July 31, 2024.
Is the Analyst Rating UroGen Pharma (URGN) correct?
While ratings are subjective and will change, the latest UroGen Pharma (URGN) rating was a maintained with a price target of $11.00 to $18.00. The current price UroGen Pharma (URGN) is trading at is $22.61, which is out of the analyst's predicted range.